NCT07198165View on ClinicalTrials.gov

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

PHASE2RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Rectal CancerRectal AdenocarcinomaRectal Cancer, RadiotherapyRectal Cancer PatientsImmunotherapyTotal Neoadjuvant TherapyTotal Neoadjuvant TreatmentTargeted TherapyChemoradiotherapy
Interventions
DRUG

PD-1 inhibitor based immunotherapy

Short-course radiotherapy (25Gy/5Fx) followed by 4 cycles of CAPOX regimen (Oxaliplatin 130mg/m² IV infusion, Capecitabine 1000mg/m² orally for 14 days, Q3w) combined with Bevacizumab (7.5mg/kg IV infusion, D1, Q3w) + PD-1 inhibitor (Toripalimab 240mg IV infusion, D1, Q3w).

Trial Locations (1)

Unknown

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT07198165 - SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | Biotech Hunter | Biotech Hunter